Oragenics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report was filed by Oragenics, Inc. on March 18, 2009, regarding corporate governance changes effective as of that date. The company is incorporated in Florida and operates from its principal executive offices in Florida.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. This report focuses exclusively on executive personnel changes and associated compensation arrangements.
Material Changes
- Executive Departure: Stanley B. Stein resigned as President, Chief Executive Officer (CEO), and Director effective March 18, 2009. The resignation was not due to any disagreement with the company.
- Transition to Advisory Role: Mr. Stein entered into a Separation Agreement ending his employment and a Consulting Agreement to provide services on an as-needed basis.
- Interim Leadership:
- David Hirsch (CFO and COO) appointed as Acting CEO.
- Dr. Robert T. Zahradnik (VP of Business Development) appointed as Acting COO.
- Compensation Details: Dr. Zahradnik's arrangement includes an annual salary of $50,000 and a grant of 150,000 stock options vesting in three tranches of 50,000 shares based on future milestones. Mr. Hirsch's financial terms remain unchanged from prior disclosures.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies beyond the standard disclosure that the executive departure was not caused by operational disagreements.
Investor Verification Checklist
- Verify the terms of the Consulting Agreement with Stanley B. Stein to understand ongoing costs or obligations.
- Review the specific performance milestones required for Dr. Zahradnik's stock option vesting.
- Confirm the timeline for a permanent CEO appointment, as the current leadership is interim.
- Check subsequent filings for any financial impact resulting from the executive transition.